利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.023 秒)

    2-cyano-3-hydroxy-enamides
    1.
    发明授权
    2-cyano-3-hydroxy-enamides 失效
    2-氰基-3-羟基 - 烯酰胺

    公开(公告)号：US5308865A

    公开(公告)日：1994-05-03

    申请号：US1564

    申请日：1993-01-06

    申请人： Robert R. Bartlett ,  David P. Kay ,  Elizabeth A. Kuo ,  Rudolf Schleyerbach ,  Wilfried Schwab

    发明人： Robert R. Bartlett ,  David P. Kay ,  Elizabeth A. Kuo ,  Rudolf Schleyerbach ,  Wilfried Schwab

    IPC分类号： A61K31/165 ,  A61K31/275 ,  A61K31/277 ,  A61P29/00 ,  C07C255/19 ,  C07C255/23 ,  C07C255/26 ,  C07C255/60 ,  C07C255/61 ,  C07C323/41 ,  C07C255/36

    CPC分类号： C07C255/19 ,  C07C255/23

    摘要： A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of ##STR2## R.sub.13, R.sub.14 and R.sub.15 are individually selected from the group consisting of hydrogen, halogen and alkyl of 1 to 3 carbon atoms, n is an integer from 1 to 3, R.sub.2 is hydrogen or alkyl of 1 to 3 carbon atoms, R.sub.3, R.sub.4 R.sub.5, R.sub.6 and R.sub.7 are individually selected from the group consisting of hydrogen, halogen, --NO.sub.2, --CN, alkyl, alkylthio and alkoxy of 1 to 6 carbon atoms, alkylcarbonyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, ##STR3## m is 0, 1, 2 or 3, n is 1, 2 or 3; Hal, Hal.sub.1, Hal.sub.2 and Hal.sub.3 are individually halogen and ##STR4## R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are individually any of the groups defined above for R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 or R.sub.4 and R.sub.5 together form --O--CH.sub.2 --O-- and their non-toxic, pharmaceutically acceptable base addition salts having anti-inflammatory activity.

    摘要翻译： 选自下列化合物的化合物的化合物其中R 1选自下组的化合物：其中R 1选自由下列组成的组：R 1，R 14和R 15分别选自氢，卤素和烷基 1至3个碳原子，n为1至3的整数，R2为氢或1至3个碳原子的烷基，R3，R4 + L，R5，R6和R7分别选自氢，卤素 ，碳原子数1〜6的烷氧基，碳原子数为2〜6的烷基羰基，碳原子数3〜6的环烷基，（CH 2）m CF 3，O（CH 2）m CF 3，S（CH 2） mCF3， m为0,1,2或3，n为1,2或3; Hal，Hal1，Hal2和Hal3分别为卤素，R8，R9，R10，R11和R12分别是R3，R4，R5，R6和R7中定义的任何基团，R4或R5一起形成-O- CH2-O-及其具有抗炎活性的无毒的药学上可接受的碱加成盐。

    Phenyl carboxamide isoxazoles
    2.
    发明授权
    Phenyl carboxamide isoxazoles 失效
    苯基甲酰胺异恶唑

    公开(公告)号：US5371099A

    公开(公告)日：1994-12-06

    申请号：US54893

    申请日：1993-04-28

    申请人： Robert R. Bartlett ,  Matharu S. Singh ,  Elizabeth A. Kuo ,  Rudolf Schleyerbach ,  Robert Westwood

    发明人： Robert R. Bartlett ,  Matharu S. Singh ,  Elizabeth A. Kuo ,  Rudolf Schleyerbach ,  Robert Westwood

    IPC分类号： A61K31/42 ,  A61P29/00 ,  C07C235/78 ,  C07C235/80 ,  C07C255/60 ,  C07C323/41 ,  C07D207/06 ,  C07D261/18 ,  C07D295/145 ,  C07D261/08 ,  C07D261/12

    CPC分类号： C07D295/145 ,  C07C235/80 ,  C07C255/60 ,  C07C323/41 ,  C07D261/18 ,  C07C2101/02

    摘要： A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 3 carbon atoms, R.sub.2 is alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, R.sub.3 is --COOR.sub.6, R.sub.6 is hydrogen or alkyl of 1 to 3 carbon atoms, R.sub.4 is selected from the group consisting of halogen, --CN, --NO.sub.2, --SCH.sub.3, alkylcarbonyl of 1 to 6 alkyl carbon atoms, --CX.sub.3, --WCX.sub.3, --(CH.sub.2).sub.n --CX.sub.3, --(CX.sub.2).sub.n --CX.sub.3, --W--(CX.sub.2).sub.n --CX.sub.3, and --W--(CH.sub.2).sub.n --CX.sub.3, X is halogen, W is --O-- or --S--, n is 1, 2 or 3, R.sub.5 is selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms and cycloalkyl of 3 to 6 carbon atoms and their salts with non-toxic pharmaceutically acceptable bases with the proviso that if R.sub.2 is alkyl of 1 to 3 carbon atoms, R.sub.1 is hydrogen and R.sub.4 is selected from the group consisting of halogen, --CX.sub.3, --(CH.sub.2).sub.n --CX.sub.3, --(CX.sub.2).sub.n --CX.sub.3, --OCX.sub.3, --O--(CX.sub.2).sub.n --CX.sub.3, and --O--(CH.sub.2).sub.n --CX.sub.3, X is halogen and n is 1, 2 or 3, R.sub.5 cannot be hydrogen having anti-inflammatory activity and their preparation and intermediates.

    摘要翻译： 选自下式的化合物的化合物其中R 1为氢或1至3个碳原子的烷基，R 2为1至3个碳原子的烷基或3至6个碳原子的环烷基，R 3为 -COOR 6，R 6是氢或1至3个碳原子的烷基，R 4选自卤素，-CN，-NO 2，-SCH 3，1至6个烷基碳原子的烷基羰基，-CX 3，-WCX 3， （CH 2）n -CX 3， - （CX 2）n -CX 3，-W-（CX 2）n -CX 3和-W-（CH 2）n -CX 3，X是卤素，W是-O-或-S-， n为1,2或3，R5选自氢，1至3个碳原子的烷基和3至6个碳原子的环烷基及其与无毒的药学上可接受的碱的盐，条件是如果R2为 1至3个碳原子的烷基，R1是氢，R4选自卤素，-CX3， - （CH2）n -CX3， - （CX2）n -CX3，-OCX3，-O-（CX2） n -CX3和-O-（CH2）n -CX3，X是卤素，n是1,2或3，R5不能是具有抗炎活性的氢 及其制备和中间体。

    5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines
    4.
    发明授权
    5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines 失效
    5-（3-烷基-5-叔丁基-4-羟基苯基）-2-氨基-6H-1,3,4-噻二嗪

    公开(公告)号：US4940790A

    公开(公告)日：1990-07-10

    申请号：US149601

    申请日：1988-01-28

    申请人： Werner Thorwart ,  Ulrich Gebert ,  Rudolf Schleyerbach ,  Robert R. Bartlett

    发明人： Werner Thorwart ,  Ulrich Gebert ,  Rudolf Schleyerbach ,  Robert R. Bartlett

    IPC分类号： A61K31/54 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  C07D285/16

    CPC分类号： C07D285/16

    摘要： Novel 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl,R.sup.2 =H or C.sub.1 -C.sub.3 -alkylR.sup.3 and R.sup.4 =independently of one another, optionally substituted and optionally O- or S-interrupted alkyl, alkenyl or alkynyl groups, it being possible for one of the two radicals to also be H,or R.sup.3 +R.sup.4 together with the nitrogen atom to which they are bound, may denote an optionally substituted 4- to 7-membered ring which optionally contains a further heteroatom (O, S or N),and the physiologically acceptable acid-addition salts thereof. The compounds are primarily suitable for prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders and/or pain.

    摘要翻译： 通式Ⅰ的新型5-（3-烷基-5-叔丁基-4-羟基苯基）-2-氨基-6H-1,3,4-噻二嗪其中R1 = C1-C4 - 烷基，R 2 = H或C 1 -C 3 - 烷基R 3和R 4彼此独立地是任选取代的，任选地O-或S-间隔的烷基，链烯基或炔基，两个基团之一也可以是 H或R 3 + R 4与它们所连接的氮原子一起可以表示任选取代的4-至7-元环，其任选地含有另外的杂原子（O，S或N）和生理上可接受的酸加成 的盐。 该化合物主要适用于预防和治疗炎症特别是炎性风湿病和/或疼痛。

    Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
    5.
    发明授权
    Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus 失效
    抵抗自身免疫疾病的药物，特别是系统性红斑狼疮

    公开(公告)号：US5268382A

    公开(公告)日：1993-12-07

    申请号：US870327

    申请日：1992-04-17

    申请人： Robert R. Bartlett ,  Rudolf Schleyerbach ,  Friedrich-Johannes Kammerer

    发明人： Robert R. Bartlett ,  Rudolf Schleyerbach ,  Friedrich-Johannes Kammerer

    IPC分类号： A61K31/275 ,  A61K31/42 ,  C07C255/23

    CPC分类号： C07C255/23 ,  A61K31/275 ,  A61K31/42

    摘要： A pharmaceutical composition for use in the treatment of chronic Graft-versus-host diseases as well as autoimmune diseases, in particular for the treatment of systemic lupus erythematosus containing as an active ingredient at least one compound of the formulae 1 or 2 ##STR1## the latter being present per se or in the form of a physiologically tolerable salt.The invention also relates to a dosage unit form of said pharmaceutical composition and a method of treating chronic Graft-versus-host diseases as well as autoimmune diseases, in particular systemic lupus erythematosus.

    摘要翻译： 一种用于治疗慢性移植物抗宿主病以及自身免疫疾病的药物组合物，特别是用于治疗系统性红斑狼疮的系统性红斑狼疮，所述系统性红斑狼疮含有至少一种式1或2化合物作为活性成分。 后者本身存在或以生理上可耐受的盐的形式存在。 本发明还涉及所述药物组合物的剂量单位形式和治疗慢性移植物抗宿主病以及自身免疫疾病，特别是系统性红斑狼疮的方法。

    Imidazo- and triazolothiadiazines
    6.
    发明授权
    Imidazo- and triazolothiadiazines 失效
    咪唑并和三唑并噻二嗪

    公开(公告)号：US4891374A

    公开(公告)日：1990-01-02

    申请号：US149546

    申请日：1988-01-28

    申请人： Werner Thorwart ,  Ulrich Gebert ,  Rudolf Schleyerbach ,  Robert R. Bartlett

    发明人： Werner Thorwart ,  Ulrich Gebert ,  Rudolf Schleyerbach ,  Robert R. Bartlett

    IPC分类号： A61K31/54 ,  A61P29/00 ,  A61P37/00 ,  C07D233/54 ,  C07D233/84 ,  C07D233/86 ,  C07D513/04

    CPC分类号： C07D513/04 ,  C07D233/84 ,  C07D233/86

    摘要： Novel imidazo- and triazolothiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl,R.sup.2 =H or C.sub.1 -C.sub.3 -alkyland the structural element --A--B--=--CH.sub.2 --CH.sub.2 --, --CH CH--, --CH.dbd.N--, --CH.sub.2 --CO-- or --CO--CH.sub.2 --,and the physiologically aceptable acid-addition salts thereof, are prepared by reacting 2-halo-1-phenylalkanones of the formula II ##STR2## (meaning of R.sup.1 and R.sup.2 as in formula I, X=halogen) with compounds of the formula III ##STR3## (meaning of --A--B-- as in formula I) and, if appropriate, converting the compounds of the formula I formed into the physiologically acceptable acid-addition salts thereof by means of suitable acids.The compounds of the formula I and the physiologically acceptable acid-addition salts thereof are principally suitable for the prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders.Some of the intermediates formed during the preparation of the compounds of the formula I are also novel, namely 1-amino-2-mercaptoimidazole ##STR4## and 1-amino-2-thioxo-5-imidazolidinone ##STR5##

    摘要翻译： 其中R 1 = C 1 -C 4 - 烷基，R 2 = H或C 1 -C 3 - 烷基和结构元素-AB - = - CH 2 -CH 2 - ， - 的通式I（I）的新型咪唑并 - 和三唑并噻二嗪， CH CH - ， - CH = N - ， - CH 2 -CO-或-CO-CH 2 - ，及其生理上可接受的酸加成盐，通过使式II的2-卤代-1-苯基烷基酮 （II）（式I中R 1和R 2的含义，X =卤素）与式III化合物（III）（式I中的-AB-的含义）反应，如果合适，将化合物 式I通过合适的酸形成生理上可接受的酸加成盐。 式I化合物及其生理上可接受的酸加成盐主要适用于预防和治疗炎症特别是炎性风湿病。 在制备式I化合物期间形成的一些中间体也是新的，即1-氨基-2-巯基咪唑和1-氨基-2-硫代-5-咪唑啉酮。

    Medicaments to combat autoimmune diseases
    8.
    发明授权
    Medicaments to combat autoimmune diseases 失效
    抵抗自身免疫性疾病的药物

    公开(公告)号：US5679709A

    公开(公告)日：1997-10-21

    申请号：US478847

    申请日：1995-06-07

    申请人： Robert R. Bartlett ,  Rudolf Schleyerbach ,  Friedrich-Johannes Kammerer

    发明人： Robert R. Bartlett ,  Rudolf Schleyerbach ,  Friedrich-Johannes Kammerer

    IPC分类号： A61K31/275 ,  A61K31/42 ,  C07C255/23 ,  A61K31/16

    CPC分类号： C07C255/23 ,  A61K31/275 ,  A61K31/42

    摘要： A pharmaceutical composition for use in the treatment of chronic Graft-versus-host diseases as well as autoimmune diseases, in particular for the treatment of systemic lupus erythematosus containing as an active ingredient at least one compound of the formula 1 or 2 ##STR1## the latter being present per se or in the form of a physiologically tolerable salt. The invention also relates to a dosage unit form of said pharmaceutical composition and a method of treating chronic Graft-versus host diseases as well as autoimmune diseases, in particular systemic lupus erythematosus.

    摘要翻译： 一种用于治疗慢性移植物抗宿主病以及自身免疫疾病的药物组合物，特别是用于治疗系统性红斑狼疮的系统性红斑狼疮，所述系统性红斑狼疮含有至少一种式1或2化合物作为活性成分。 后者本身存在或以生理上可耐受的盐的形式存在。 本发明还涉及所述药物组合物的剂量单位形式和治疗慢性移植物抗宿主病以及自身免疫性疾病，特别是系统性红斑狼疮的方法。